Page 127 - 南京医科大学学报自然科学版
P. 127
第42卷第6期 夏 鹏,唐立钧,丁重阳,等. F⁃FDG PET/CT预测肺腺癌EGFR基因突变状态的研究进展[J].
18
2022年6月 南京医科大学学报(自然科学版),2022,42(06):875-879 ·879 ·
2014,41(11):2058-2065 (1):370-380
[17] LEE S M,BAE S K,JUNG S J,et al. FDG uptake in non⁃ [25] SASAKI H,SHITARA M,YOKOTA K,et al. Overexpres⁃
small cell lung cancer is not an independent predictor of sion of GLUT1 correlates with KRAS mutations in lung
EGFR or KRAS mutation status:a retrospective analysis carcinomas[J]. Mol Med Rep,2012,5(3):599-602
of 206 patients[J]. Clin Nucl Med,2015,40(12):950-958 [26] KIM Y I,PAENG J C,PARK Y S,et al. Relation of EG⁃
[18] HUANG C T,YEN R F,CHENG M F,et al. Correlation of FR mutation status to metabolic activity in localized lung
18
F⁃fluorodeoxyglucose⁃positron emission tomography max⁃ adenocarcinoma and its influence on the use of FDG PET/
imal standardized uptake value and EGFR mutations in CT parameters in prognosis[J]. AJR Am J Roentgenol,
advanced lung adenocarcinoma[J]. Med Oncol,2010,27 2018,210(6):1346-1351
(1):9-15 [27] LIU A,HAN A Q,ZHU H,et al. The role of metabolic tu⁃
18
18
[19] KO K H,HSU H H,HUANG T W,et al. Value of F⁃FDG mor volume(MTV)measured by F⁃FDG PET/CT in pre⁃
uptake on PET/CT and CEA level to predict epidermal dicting EGFR gene mutation status in non⁃small cell lung
growth factor receptor mutations in pulmonary adenocarci⁃ cancer[J]. Oncotarget,2017,8(20):33736-33744
noma[J]. Eur J Nucl Med Mol Imaging,2014,41(10): [28] 姜 阳,马晓伟,董楚宁,等. 基于 F⁃FDG PET⁃CT代谢
18
1889-1897 参数的风险模型对非小细胞肺癌EGFR基因突变的预
18
[20] NA I I,BYUN B H,KIM K M,et al. F⁃FDG uptake and 测价值及效能评价[J]. 中华放射学杂志,2020,54(7):
EGFR mutations in patients with non⁃small cell lung can⁃ 688-693
cer:a single ⁃ institution retrospective analysis[J]. Lung [29] YANG B,WANG Q G,LU M J,et al. Correlations study
18
Cancer,2010,67(1):76-80 between F⁃FDG PET/CT metabolic parameters predict⁃
[21] MAK R H,DIGUMARTHY S R,MUZIKANSKY A,et al. ing epidermal growth factor receptor mutation status and
18
Role of F⁃fluorodeoxyglucose positron emission tomogra⁃ prognosis in lung adenocarcinoma[J]. Front Oncol,2019,
phy in predicting epidermal growth factor receptor muta⁃ 9:589
tions in non⁃small cell lung cancer[J]. Oncologist,2011, [30] LIU Q F,SUN D Z,LI N,et al. Predicting EGFR mutation
18
16(3):319-326 subtypes in lung adenocarcinoma using F⁃FDG PET/CT
[22] TAKAMOCHI K,MOGUSHI K,KAWAJI H,et al. Corre⁃ radiomic features[J]. Transl Lung Cancer Res,2020,9
18
lation of EGFR or KRAS mutation status with F⁃FDG up⁃ (3):549-562
take on PET⁃CT scan in lung adenocarcinoma[J]. PLoS [31] ZHAO H Y,SU Y X,ZHANG L H,et al. Prediction model
18
One,2017,12(4):e0175622 based on F⁃FDG PET/CT radiomic features and clinical
[23] AMANN T,MAEGDEFRAU U,HARTMANN A,et al. factors of EGFR mutations in lung adenocarcinoma[J].
GLUT1 expression is increased in hepatocellular carcino⁃ Neoplasma,2022,69(1):233-241
ma and promotes tumorigenesis[J]. Am J Pathol,2009, [32] 尹国涛,徐文贵,朱 磊,等. F⁃FDG PET/CT对肺腺癌
18
174(4):1544-1552 EGFR 突变状态的预测价值研究[J]. 中国肿瘤临床,
[24] CHEN L,ZHOU Y C,TANG X X,et al. EGFR mutation 2018,45(14):717-720
decreases FDG uptake in non⁃small cell lung cancer via [收稿日期] 2022-02-23
the NOX4/ROS/GLUT1 axis[J]. Int J Oncol,2019,54 (本文编辑:陈汐敏)